{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:07Z","timestamp":1792790527143,"version":"4.5.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer, often developing from androgen receptor (AR) independence, characterized by neuroendocrine molecular markers and nonresponsiveness to standard treatments of prostate adenocarcinoma. The evolution of adenocarcinoma to NEPC is characterized by epigenetic changes, leading to the downregulation of the PSMA transmembrane protein, as well as the upregulation of FDG-uptake pathways and somatostatin receptor expression. We present a case of NEPC that depicts a significant metastatic intertumoral heterogeneity as depicted on PSMA, FDG, and DOTATATE PET\/CT scans. Such multiprobe PET evaluation of NEPC may assist in sampling the most aggressive disease and guide an appropriate management strategy. It also provides a cellular-level insight into this dreadful disease with very limited treatment options.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006182","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T15:00:10Z","timestamp":1763996410000},"page":"e159-e162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Multiprobe PET Imaging"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-4918","authenticated-orcid":false,"given":"Akshay","family":"Bedmutha","sequence":"first","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Barron","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Pathology, VA Medical Center, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Oi","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7289-243X","authenticated-orcid":false,"given":"David","family":"Brandon","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"R1-20260203","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2967\/jnumed.117.206631","article-title":"SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework","volume":"59","author":"Werner","year":"2018","journal-title":"J Nucl Med"},{"key":"R2-20260203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF sSignaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"R4-20260203","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/PAS.0b013e3181e6cbf3","article-title":"NKX3.1 as a marker of prostatic origin in metastatic tumors","volume":"34","author":"Gurel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R7-20260203","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J Clin Invest"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.3390\/cancers15174404","article-title":"PET\/CT and conventional imaging for the assessment of neuroendocrine prostate cancer: a systematic review","volume":"15","author":"Dondi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R10-20260203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:00:30Z","timestamp":1770141630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006182"}},"subtitle":["Insignia of Tumor Heterogeneity in a Case of Neuroendocrine Prostate Cancer"],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006182","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2025-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}